An appendix to the 2012 IOF-ECTS guidelines for the management of glucocorticoid-induced osteoporosis.
Lekamwasam S., Adachi JD., Agnusdei D., Bilezikian J., Boonen S., Borgström F., Cooper C., Perez AD., Eastell R., Hofbauer LC., Kanis JA., Langdahl BL., Lesnyak O., Lorenc R., McCloskey E., Messina OD., Napoli N., Obermayer-Pietsch B., Ralston SH., Sambrook PN., Silverman S., Sosa M., Stepan J., Suppan G., Wahl DA., Compston JE., Joint IOF–ECTS GIO Guidelines Working Group None.
The use of glucocorticoids in the treatment of medical disorders can lead to rapid bone loss and increased risk of fragility fracture. Updated clinical guidelines are needed that accommodate recent advances in fracture risk assessment and new pharmacological interventions to reduce fracture risk. This document serves as an appendix to the 2012 IOF-ECTS guidelines for the management of glucocorticoid-induced osteoporosis.